Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. [electronic resource]
Producer: 20190423Description: 1008-1019 p. digitalISSN:- 1525-0024
- Adaptive Immunity
- Animals
- Cell Line, Tumor
- Disease Models, Animal
- Gene Expression
- Genetic Therapy -- adverse effects
- Genetic Vectors -- administration & dosage
- Humans
- Injections, Intralesional
- Lymphocyte Activation -- genetics
- Melanoma, Experimental
- Mice
- Neoplasms -- immunology
- Newcastle disease virus -- genetics
- Oncolytic Virotherapy -- adverse effects
- Oncolytic Viruses -- genetics
- T-Lymphocyte Subsets -- immunology
- Transgenes
- Treatment Outcome
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.